Back to News
Market Impact: 0.4
argenx Meets Primary Endpoint in Phase II Celiac Disease Study
Source: zacks.com
Healthcare & BiotechCompany Fundamentals
ARGX's FB102 met its primary endpoint in a Phase II celiac disease study, supporting progression toward late-stage development. Despite the trial result, ARGX shares fell nearly 12%; the article does not state the reason for the decline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.00
More News
- Wall Street Week | Michigan Manufacturing, AI Debt Investments, Baby Bonds, Canadian Coal Fight
- Tesla drops 'Full Self-Driving' brand name in Europe after regulator pushback
- SpaceX makes big move into wireless. These once 'obsolete' tech stocks could benefit
- Why is T-Mobile stock tumbling today?
- Wall Street sees buying opportunity in banks as shares tank ahead of earnings
- MTY Food Group Inc Profit Retreats In Q3